Skip to main content
Equibles
KYTX logo

KYTX · Kyverna Therapeutics, Inc.

Track KYTX — free

Use KYTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KYTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.13 +0.09 (+1.28%) At close · Sep 18
Russell 2000 member Rebalance outlook locked
Market Cap
$440.94M
Shares
61.84M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.13 Open$7.02 Day$7.00–7.19 52W close$5.01–11.25 Avg vol 30d733K Short int8.5M · 13.7% float · 12.4d Short vol72% Last earningsApr 22, 2026 DataFeb 2024–Sep 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$152.64M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$174.54M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+40.9%
Year over year · more shares
Price change (1Y)
+42.3%
Trailing year
Short interest
13.7%
Latest settlement · 12.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −15%
below
Price vs 50-day avg −9%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 34%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −12%
trailing
6-month return −9%
trailing
YTD return −24%
this year
Relative strength −29%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+7% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
13.67% of float · ▼ -0.5% MoM · 12.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
120 holders — near 2-yr high, broad support
Squeeze score 69
elevated · 0–100
Fundamentals
Poor
EPS growth −9%
Y/Y
Free cash flow $-153.7M
Quant / Vol
risk profile
Very High
Volatility 99%
annualized · 1-yr
Max drawdown −39%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−15% Bearish
Price vs 50-day avg
−9% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
34% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+7% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
13.67% of float · ▼ -0.5% MoM · 12.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
120 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $5 Now $7 · 34% Range high $11
vs 200-day avg -15% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KYTX
Kyverna Therapeutics, Inc.
this stock
$440.94M -24.1% — — 13.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.06B +12.1% +46.2% 29.9 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.80B +1.7% +20.8% 19.4 2.5%
MRNA
Moderna, Inc.
 $61.50B +422.3% +4.3% — 9.8%
ARGX
Argenx SE
 $60.93B +17.8% — — 2.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
120
% held
61.3%
Net QoQ
+2.9M sh
Top holder
GordonMD Global Investmen…
Held Float
View
Held by Funds
Fund positions
95
View
Short & Settlement
Short Interest Falling
Shares short
8.5M
Days to cover
12.4d
Change
-44.5K sh
View
Short Volume
Short vol %
72%
As of
Sep 18, 2026
Short Total
View
Fails to Deliver
FTD shares
4.8K
Value
$39.2K
As of
Aug 25, 2026
View
Off-Exchange
Off-exchange %
42.7%
Week of
Aug 10, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-161.3M
EPS diluted
$-3.64
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 14, 2026
This year
22
View
Proposed Sales
Value
$95.3K
Shares
10.0K
Filed
Apr 17, 2026
View
Exempt Offerings
Offering
$152.0M
Filed
Nov 7, 2023
View
Earnings & Events
Earnings Calls
Last call
Sep 14, 2026
View

Performance

5D 20D 120D MTD YTD
KYTX -1.8% -12.3% -8.6% -15.9% -24.2%
SPY -0.3% -0.1% +20.1% -0.7% +11.7%
vs SPY -1.5% -12.2% -28.7% -15.2% -35.9%
Key facts CIK 1994702 CUSIP 501976104 13F (30d) 4 filings 4 filers Visit website Investor relations